ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. The company specialises in high quality medicines for the treatment of important diseases in the livestock sector. ECO Animal Health are dedicated to the research, development and marketing of strong brands, differentiated generics and innovative new solutions.

06 Nov 2026

China weakness but profitability maintained

In a trading update for the six months to 30 September, ECO Animal Health reports revenue of £33.0m, -15%YoY (H1 26: £39.0m), resulting from a decline in revenue from China/Japan, partially offset by overall 6%YoY growth elsewhere including over 50%YoY growth in South & South East Asia.

Gross margin improved to c.52% (H1 26: 49.6%) whilst (adj.) EBITDA of c.£3.0m matched H1 26 (£2.96m), and cash stood at £24m (FY26: £25.5m).

Of note, the first of the range of new products under development, ECOVAXXIN®MS, recorded initial EU sales.

The Group expects FY27 revenue from the China/Japan region to be less than half of FY26 (FY26: £24.1m, 27.5% of total) resulting in overall revenue below market consensus of £89.6m. However, (adj.) EBITDA of £8.5m is expected to be broadly in line with consensus, as is EPS of 3.30p.

Download as a PDF file

Return to ECO Animal Health

Register to be first

Get research on the companies that interest you straight to your inbox

Equity Development is a partner to successful companies looking to enhance their investor relations. Our top-rated analysts produce best in class investment research. Based in London, UK, we help our clients connect with investors via presentations and interviews.

Equity Development Limited 3rd Floor, 80 Cheapside, London, EC2V 6EE